Venlafaxine
- Generic Name
- Venlafaxine
- Brand Names
- Effexor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO2
- CAS Number
- 93413-69-5
- Unique Ingredient Identifier
- GRZ5RCB1QG
- Background
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...
- Indication
Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
- Associated Conditions
- Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)
- Conditions
- Interventions
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 30
- Registration Number
- NCT06131268
- Locations
- 🇮🇹
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, MI, Italy
REDucing Hot FLASHes in Women Using Endocrine Therapy.
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Reinier de Graaf Groep
- Target Recruit Count
- 260
- Registration Number
- NCT06106529
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Conditions
- Interventions
- Drug: FezolinetantDrug: ParoxetineDrug: GabapentinDrug: CitalopramDrug: ClonidineDrug: PregabalinDrug: EscitalopramDrug: DesvenlafaxineDrug: OxybutyninDrug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category aboveDrug: VenlafaxineDrug: Any other SSRI/SNRI not already specified
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT06049797
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸SUNY Downstate Health Sciences University, Brooklyn, New York, United States
🇺🇸Mohawk Valley Health System - Womens Health Center, Utica, New York, United States
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 418
- Registration Number
- NCT05973786
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany
Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 60
- Registration Number
- NCT05884268
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT05724849
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 1254
- Registration Number
- NCT05603104
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 52
- Registration Number
- NCT05569031
- Locations
- 🇪🇬
Faculty of medicine, Zagazig, Sharkia, Egypt
Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Scotmann Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT05104918
Mood Disorders in Head and Neck Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 205
- Registration Number
- NCT04977271
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.